The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Questcor Pharmaceuticals's revenues will grow 50.6% and EPS will increase 44.6%.
The average estimate for revenue is $169.4 million. On the bottom line, the average EPS estimate is $0.94.
Last quarter, Questcor Pharmaceuticals booked revenue of $135.1 million. GAAP reported sales were 41% higher than the prior-year quarter's $96.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.65. GAAP EPS of $0.65 for Q1 were 12% higher than the prior-year quarter's $0.58 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 88.0%, 620 basis points worse than the prior-year quarter. Operating margin was 43.9%, much worse than the prior-year quarter. Net margin was 28.9%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $662.5 million. The average EPS estimate is $3.64.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 497 members out of 550 rating the stock outperform, and 53 members rating it underperform. Among 151 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 127 give Questcor Pharmaceuticals a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $45.38.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Questcor Pharmaceuticals. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Questcor Pharmaceuticals to My Watchlist.